知Yizhi Daily
← Back to this edition

AI

Science Corporation raises $400 million, with brain-computer interface and vision restoration business valued at $3.5 billion

Edition 2026-11-18 · 08:00 Beijing time

Science Corporation, a medical technology company founded by former Neuralink president Max Hodak, has completed $400 million in Series D financing at a post-money valuation of $3.5 billion. The funds will be used to bring the PRIMA vision restoration device to the United States and develop a biohybrid brain sensor made of cultured neurons and silicon.

Investors in this round include Khosla Ventures, Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech. Founded in 2021, the company aims to use new technologies to understand and interact with the brain.

Science’s first product, PRIMA, consists of wearable and implantable chips and is used to help patients with age-related macular degeneration regain partial vision. The device has been approved in Europe and is available in Germany, while new indications are also being explored.

Company founder Max Hodak said at TechCrunch Disrupt that PRIMA is being tested in patients with Stargardt disease, another condition that can cause blindness. The company also plans to enter the United States through the FDA’s humanitarian device exemption pathway, saying it has explained to the FDA that advanced macular degeneration in both eyes is rare enough to seek approval for use on that basis.

The longer-term direction is direct connection to the human brain. Science is working with Murat Günel, a Yale neurosurgery professor, to design the first human trial of its biohybrid sensor; Günel believes the technology could offer potential treatment ideas for Parkinson’s disease and other brain injuries and disorders.

Original sources

TechCrunch ↗
Back to this editionOpen interactive reader